NASDAQ:CTMXCytomX Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CytomX Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.41 -0.11 (-1.29 %) (As of 07/3/2020 08:59 AM ET) Add Compare Share Today's Range$8.38Now: $8.41▼$8.6750-Day Range$7.51MA: $8.65▼$14.4452-Week Range$3.60Now: $8.41▼$15.44Volume449,157 shsAverage Volume680,552 shsMarket Capitalization$386.19 millionP/E RatioN/ADividend YieldN/ABeta0.69 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingCytomX Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.38, CytomX Therapeutics has a potential upside of 47.1% from its current price of $8.41.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesCytomX Therapeutics has received 339 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCytomX Therapeutics has received 261 “underperform” votes. (Add your “underperform” vote.)Community SentimentCytomX Therapeutics has received 56.50% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote “Outperform” if you believe CTMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $540,000.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions78.59% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.48) to ($2.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytomX Therapeutics has a P/B Ratio of 7.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTMX Previous Symbol CUSIPN/A CIK1501989 Webwww.cytomx.com Phone650-515-3185Debt Debt-to-Equity Ratio0.35 Current Ratio3.77 Quick Ratio3.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$57.49 million Price / Sales6.72 Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book7.51Profitability EPS (Most Recent Fiscal Year)($2.26) Net Income$-102,240,000.00 Net Margins-97.83% Return on Equity-99.72% Return on Assets-19.52%Miscellaneous Employees137 Outstanding Shares45,920,000Market Cap$386.19 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:CTMX Rates by TradingView Receive CTMX News and Ratings via Email Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions How has CytomX Therapeutics' stock been impacted by COVID-19 (Coronavirus)? CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CTMX stock has increased by 43.3% and is now trading at $8.41. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of CytomX Therapeutics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CytomX Therapeutics. When is CytomX Therapeutics' next earnings date? CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for CytomX Therapeutics. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics Inc (NASDAQ:CTMX) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.60. The biotechnology company had revenue of $49.59 million for the quarter, compared to analysts' expectations of $26.93 million. CytomX Therapeutics had a negative return on equity of 99.72% and a negative net margin of 97.83%. View CytomX Therapeutics' earnings history. What price target have analysts set for CTMX? 9 analysts have issued 12-month price targets for CytomX Therapeutics' stock. Their forecasts range from $7.00 to $16.00. On average, they expect CytomX Therapeutics' share price to reach $12.38 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price. View analysts' price targets for CytomX Therapeutics. What are Wall Street analysts saying about CytomX Therapeutics stock? Here are some recent quotes from research analysts about CytomX Therapeutics stock: 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (6/26/2020) 2. Nomura Securities analysts commented, "Progressing IO Probody CX-072—next steps 2H19: CX-072 (PD-L1) in combo with full dose ipi (3mg/kg) is well tolerated—plans for next phase of combo will be revealed in near future. We view undifferentiated pleomorphic sarcoma as offering potentially easier CX-072 combo differentiation vs ipi/PD- (L)1, where this combo has not been tolerated. Monotherapy next steps in 2H19, but based on single-arm expansion data, we still see oppy for monotherapy strategy (e.g., autoimmune disease pts/pts intolerant to PD-1). Solid tumor candidate Ph2 dose, indication: Ph2 registration-worthy? Recall, CTMX saw responses to CX- 2009 in solid-tumor pts including those who failed TROP2 from IMMU. CX- 2009 still in dose refinement, starting at 8mg/kg and using a modified toxicity probability interval (mTPI) design." (8/11/2019) Has CytomX Therapeutics been receiving favorable news coverage? Press coverage about CTMX stock has trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. CytomX Therapeutics earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about CytomX Therapeutics. Who are some of CytomX Therapeutics' key competitors? Some companies that are related to CytomX Therapeutics include Intercept Pharmaceuticals (ICPT), Kiniksa Pharmaceuticals (KNSA), BELLUS Health (BLUSF), Mersana Therapeutics (MRSN), Heron Therapeutics (HRTX), Karyopharm Therapeutics (KPTI), Revance Therapeutics (RVNC), ZEALAND PHARMA/S (ZEAL), MacroGenics (MGNX), Innoviva (INVA), Portola Pharmaceuticals (PTLA), Esperion Therapeutics (ESPR), Akcea Therapeutics (AKCA), Cytokinetics (CYTK) and Amneal Pharmaceuticals (AMRX). View all competitors. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), SCYNEXIS (SCYX), Bausch Health Companies (BHC) and Cidara Therapeutics (CDTX). Who are CytomX Therapeutics' key executives? CytomX Therapeutics' management team includes the following people: Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)Mr. Debanjan Ray, Sr. VP & CFO (Age 41)Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63) What is CytomX Therapeutics' stock symbol? CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX." How do I buy shares of CytomX Therapeutics? Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CytomX Therapeutics' stock price today? One share of CTMX stock can currently be purchased for approximately $8.41. How big of a company is CytomX Therapeutics? CytomX Therapeutics has a market capitalization of $386.19 million and generates $57.49 million in revenue each year. The biotechnology company earns $-102,240,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe. What is CytomX Therapeutics' official website? The official website for CytomX Therapeutics is www.cytomx.com. How can I contact CytomX Therapeutics? CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected] This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
